- Home
- CCEC vs JANX Comparison
CCEC vs JANX Comparison
Compare CCEC & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCEC
- JANX
- Stock Information
- Founded
- CCEC 2007
- JANX 2017
- Country
- CCEC Greece
- JANX United States
- Employees
- CCEC N/A
- JANX N/A
- Industry
- CCEC Marine Transportation
- JANX Biotechnology: Pharmaceutical Preparations
- Sector
- CCEC Consumer Discretionary
- JANX Health Care
- Exchange
- CCEC Nasdaq
- JANX Nasdaq
- Market Cap
- CCEC 1.4B
- JANX 1.4B
- IPO Year
- CCEC 2007
- JANX 2021
- Fundamental
- Price
- CCEC $21.33
- JANX $24.00
- Analyst Decision
- CCEC Buy
- JANX Strong Buy
- Analyst Count
- CCEC 1
- JANX 11
- Target Price
- CCEC $26.00
- JANX $76.55
- AVG Volume (30 Days)
- CCEC 13.8K
- JANX 777.4K
- Earning Date
- CCEC 11-07-2025
- JANX 11-05-2025
- Dividend Yield
- CCEC 5.62%
- JANX N/A
- EPS Growth
- CCEC 62.73
- JANX N/A
- EPS
- CCEC 4.04
- JANX N/A
- Revenue
- CCEC $424,701,000.00
- JANX $439,000.00
- Revenue This Year
- CCEC $17.10
- JANX N/A
- Revenue Next Year
- CCEC $13.73
- JANX $130.50
- P/E Ratio
- CCEC $12.66
- JANX N/A
- Revenue Growth
- CCEC 84.28
- JANX N/A
- 52 Week Low
- CCEC $14.09
- JANX $21.73
- 52 Week High
- CCEC $24.83
- JANX $71.71
- Technical
- Relative Strength Index (RSI)
- CCEC 45.14
- JANX 51.94
- Support Level
- CCEC $21.60
- JANX $23.00
- Resistance Level
- CCEC $22.88
- JANX $25.35
- Average True Range (ATR)
- CCEC 1.00
- JANX 1.20
- MACD
- CCEC -0.02
- JANX 0.08
- Stochastic Oscillator
- CCEC 29.69
- JANX 62.71
About CCEC Capital Clean Energy Carriers Corp. Common Share
Capital Clean Energy Carriers Corp is an international shipping company. It is the platform of gas carriage solutions with a focus on the energy transition. The company owns 20 high-specification vessels, including 12 latest-generation LNG carriers (LNG/Cs) and eight legacy Neo-Panamax container vessels.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.